IDH1 and central nervous system cancer: For example, patient 72 with IDH-mutant-noncodel glioma had a cf-tDNA sample with two transient MMR mutations (VAF 0.1%) during the TMZ treatment, but the two mutations disappeared in the following cf-tDNA samples and did not cause many mutations.